drugset
drugset / Trial / NCT06501573

A Study of SGB-9768 in Adult Healthy Volunteers

NCT06501573 ↗

Phase 1 Active not recruiting 37 enrolled Suzhou Sanegene Bio Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled single ascending dose study of SGB-9768 in healthy volunteers. The purpose is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered SGB-9768.

Timeline

Start
2024-08-06
Primary completion
2025-05-03
Completion
2025-10-17

Drugs

EvaluationDrugModalityDoseRoute
Subject SGB-9768 Unknown — Subcutaneous

Indications

No indication recorded.